 |
We are advised by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that journalists and other readers should disregard the news release, Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer, issued 12-Jun-2025 over PR Newswire.
source: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
【說說心理話】舉辦「XO異彩藝術家奬」，讓「腦力多元」人士透過創作藝術建立自信，將負面的能量化為正向► 即睇
